EXPERT SPEAKERS
Dai Hayward
Chief Executive officer
Micropore technologies Ltd
Dai graduated in Chemistry and Physiology, has an MBA, and is a Fellow of the UK’s Royal Society of
Chemistry. Dai’s career has been spent in chemistry and biology related businesses. He has been Awarded the
Commercial Development & Marketing Association (USA) Golden C Award for professional excellence in
commercial development. As a past Chairman of the UK Chemical Industry Association’s Responsible Care
Board, a consistent theme has been to achieve more with less while increasing shareholder value. In Micropore
Technologies Dai has found a real opportunity to continue to deliver against this theme, while also working
towards the “100 day response” challenge set out by CEPI.
Dr. Otmane Boussif
Chief Technology Officer CMC Biologics - Cell & Gene Therapies
Anjarium Biosciences
Dr. Otmane Boussif, currently serving as the Chief Technical Officer at Anjarium Biosciences AG, a
company developing a new cell-free synthetic DNA platform for Cell & Gene Therapy (CGT)
modalities production. With over 25 years of experience, Dr. Boussif has played pivotal roles in
various leading companies.
At Novartis, he held several significant positions, including Global Head of Cell and Gene Therapy
Technical Development and Global Head of Early Phase Development. His expertise spans biologics,
CGT process development, characterization, and validation. Dr. Boussif’s leadership has been
instrumental in successfully advancing projects from preclinical stages to commercialization and life
cycle management (LCM).
Dr. Pierre Wils
Global Scientific Advisory Lead - mRNA Center of Excellence
Sanofi
Pierre graduated from the Institut National Agronomique in Paris, France and received his PhD in Molecular
and Cellular Pharmacology at the Institut Gustave Roussy. He has over 30 year experience in the pharmaceutical
industry, and held positions in preformulation and formulation development for both small molecules and
biotherapeutics, including gene delivery technologies. He was involved in the CMC development and
contributed to the successful filing and approval of several drugs, such as Jevtana, Kevzara or Sarclisa.
Dr. Jean-rené Authelin
Senior Scientific Advisor, global CMC,
Sanofi
Jean René Authelin has an Engineer degree in chemical Engineering from ENSIC (Nancy
France), and a PhD from The Institut National Polytechnique de Lorraine (France). He joined
Rhone Poulenc in 1988 as a Chemical Engineer. In the 90’s he founded the Physical Quality
function, dedicated to the API crystallization, drying, polymorphism, particle engineering…
for which he was for 10 years Global Head in Rhone Poulenc Rorer, Aventis and finally
sanofi . In, 2008 JR Authelin was nominated Global Head of Pharmaceutical Engineering.
Since 2020 JR Authelin is Senior Scientific Advisor, global CMC, reporting to the global
CMC head.
![Mostafa[55226]](https://parainjecto.biotrains.com/wp-content/uploads/2024/04/Mostafa55226.jpg "Mostafa[55226]")
Dr. Tathagata Dutta
Dr. Mostafa Nakach
Global head of process engineering for biologic drug product development
Sanofi
Mostafa Nakach is PhD from Toulouse University. He has prepared his thesis on stabilization and production of
nanocrystalline suspension. He is also Master 2 graduate from Paris-sud 11 university in Pharmacotechnie and
Biopharmacy and Pharmaceutical engineer from Ecole des Mines d’Albi. Mostafa has been working within the
Sanofi group for 34 years. Currently, Mostafa is working within biologic drug product development as head of
formulation & process development. His mission is to build and to manage the required skills and capabilities in
order to support R&D projects development mainly for Fill & finish lab & commercial process development of
biotech products including freeze drying.
Chief Technology Officer (CTO), JODAS EXPOIM PVT LTD
Dr. Tathagata Dutta has earned his M.Pharm and PhD in Pharmaceutical Sciences from Dr. Hari Singh Gour University, Sagar and completed his postdoctoral studies from School of pharmacy & Diamantina Institute for cancer, Immunology and Metabolic Medicine, University of Queensland, Brisbane, Australia and was engaged in development of RNAi therapeutics for effective management of cancer. He has served as Chief Scientific Officer (CSO), Vice President (R&D), Executive Director, Managing Director & CEO of several reputed Multinational Pharmaceutical Companies for more than two decades. He has been conferred with several National and International Awards and Honors. He has published several international papers in reputed international journals, several patents and had authored several book chapters. He is the editorial board member of several international journals on drug discovery & delivery research. His research interests include novel drug delivery systems, dendrimers, liposomes, polymer bioconjugates, tissue targeted drug delivery systems, nano drug delivery systems, gene therapy, genetic immunization, depot injections, gene delivery, and development of RNAi therapeutics. Presently, he is the Chief Technology Officer (CTO) of JODAS EXPOIM Pvt Ltd.
Dr. Krishna Murthy Bhavanasi
Dr. Tathagata Dutta
Chief Technology Officer (CTO) JODAS EXPOIM
Dr. Tathagata Dutta has earned his M.Pharm and PhD in Pharmaceutical Sciences from Dr. Hari Singh Gour University, Sagar and completed his postdoctoral studies from School of Pharmacy & ; Diamantina Institute for cancer, Immunology and Metabolic Medicine, University of Queensland, Brisbane, Australia and was engaged in development of RNAi therapeutics for effective management of cancer. He has served as Chief Scientific Officer (CSO), Vice President (R&D), Executive Director, Managing Director &; CEO of several reputed Multinational Pharmaceutical Companies for more than two decades. He has been conferred with several National and International Awards and Honors. He has published several international papers in reputed international journals, several patents and had authored several book chapters. He is the editorial board member of several international journals on drug discovery and; delivery research. His research interests include novel drug delivery systems, dendrimers, liposomes, polymer bioconjugates, tissue targeted drug delivery systems, nano drug delivery systems, gene therapy, genetic immunization, depot injections, gene delivery, and development ofRNAi therapeutics. Presently, he is the Chief Technology Officer (CTO) of JODAS EXPOIM Pvt Ltd.
Vice President & HEAD – FR & D Department, NATCO Pharma Ltd
Dr. Krishna Murthy Bhavanasi earned his Ph.D. in Pharmaceutical Sciences from University Science Malaysia, Penang, Malaysia. He has 21+ years of experience in production, teaching, R&D consultancy, and formulation research & development areas in India and abroad. Previously, he worked as an R&D Consultant in Malaysian Pharmaceutical Industries, Penang Malaysia. During the last 17 years of his stint at Aurobindo and Natco pharma, he handled various dosage forms viz. IR tablets, capsules, oral liquid, dry syrups, suspensions, MR/ER/DR tablets & capsules, ODTs, sublingual tablets, liquid and lyophilized injectable dosage forms, prefilled syringes, cartridge-based pen injectors and PFS-based auto-injectors. To develop these dosage forms, various technologies have been adopted (solid dispersion by HME and Spray drying, spray coating, Lyophilisation, modified dosage forms using Matrixing, reservoir technology, Nanonisation, etc) to file ANDA, NDA, and NDA’s in the USA, Europe, Canada, Australia, Brazil, WHO and ROW countries. He has filed more than 50 patent publications in novel dosage forms for various molecules. He is the recipient of many awards during his studies and during his professional career. He was rewarded with a Silver Jubilee award from Andhra University for being a topper in M. Pharm, and Vice Chancellor Graduate fellowship from USM for academic excellence. Awarded consecutively for two years for Best Patent publication in Aurobindo Pharma. In 2017 he received an “outstanding achievement award” in Formulation Research & Development in FDD Conclave.
Sekhar Babu Puli
General Manager And Head, MSN Laboratories Pvt Ltd
Sekhar Babu Puli has 20 years of industrial experience in the field of Pharmaceutical Packaging Research & Development. Currently working as the General Manager & Head – Packaging Development at MSN Laboratories. Having rich experience in Packaging Development right from concept design to ultimate product approval and commercial supply. Has been proficient in a wide variety of dosage forms within the pharmaceutical world and has successfully led numerous projects by adapting the right packaging solutions. Responsible for evaluation, design, development, optimization, and qualifications of packaging components for pharmaceutical dosage forms considering regulatory, ecological, economical & technical aspects with respect to material and machine science. Has been rewarded with the PPL Leadership Award 2020 as Game Changer of Pharma Packaging, organized by the Indian Express group. Has won 2 India Packaging Awards for the year 2021 for excellence in packaging design & Packaging Team of the Year 2021. Addressed as an expert speaker in multiple forums like Invention Business Intelligence, Informa Markets - Innopack, Messe Muenchen India & IPMMI, etc. Prior to MSN, he worked with companies like Strides Pharma Science, Astron Research Limited, and Aurobindo Pharma. Has done Master in Pharmaceutical Management from IPER and holds a Graduate in Science and also a Graduate in Packaging Technology from the Indian Institute of Packaging (IIP), Mumbai.
SUBMIT SPEAKING PROPOSAL
Challenges and Opportunities in Developing Complex injectables
Regulatory Landscape and Guidance of Complex Injectables
Lifecycle Management of Combination product Development
Primary Packaging and CMC considerations for Injectables
Scale-up and technology Transfer Challenges of Injectables
Digital Technologies to design Novel Drug-Device Combination products.
Latest technologies for next generation device design
SPEAKER OPPORTUNITIES
- As a speaker play an active role in shaping industry leading-event
- Be Internationally recognized as industry thought leader
- Network with cross-industry peers across the industry
- Have your profile features in the conference website, brochure and marketing campaigns.
- Have your expertise highlighted via webinars, thought leader articles or exclusive interviews issued on our magazine and online portal.
- Gain a discounted/complimentary pass (inclusive of access to all sessions, seated meals, networking drinks, a certification, and a PDF copy of all presentations [post-event) to the conference and additional discounted pass to share with colleagues.
